Update shared on 02 Dec 2025
Fair value Decreased 12%Analysts have lowered their price target for Protalix BioTherapeutics from $12.50 to $11.00, citing a slight reduction in expected revenue growth and profit margins.
What's in the News
- Protalix BioTherapeutics and Chiesi Global Rare Diseases have requested a re-examination of the negative opinion by the European Medicines Agency regarding the new dosing regimen for Elfabrio. They aim to add an every 4 weeks dosing option alongside the currently approved biweekly regimen (Key Developments).
- Clinical trials of Elfabrio reported various hypersensitivity and infusion-associated reactions, including anaphylaxis, and highlighted the need for careful monitoring of kidney function during treatment (Key Developments).
- Protalix BioTherapeutics was recently added to the S&P Global BMI Index, reflecting its growing recognition in the biotechnology sector (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has decreased from $12.50 to $11.00. This reflects reduced expectations for the company’s valuation.
- The discount rate has risen slightly, increasing from 7.06% to 7.13%.
- Revenue growth projections have fallen notably, moving from 8.19% to 6.65%.
- Net profit margin estimates have edged down from 35.40% to 34.04%.
- The future P/E ratio has decreased modestly, dropping from 48.69x to 46.60x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.